跳至主要内容
临床试验/jRCTs031180263
jRCTs031180263已完成不适用

Phase 2 study of S-IROX as down staging chemotherapy for borderline resectable pancreatic cancer (BR-SIROX)

未提供0 个研究点目标入组 24 人开始时间: 2018年5月28日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
24
主要终点
-

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
Single Arm Study
干预模型
Single Assignment
主要目的
Treatment Purpose
盲法
Open(masking Not Used)

入排标准

年龄范围
20age old over 至 75age old under(—)
性别
All

入选标准

  • 1 Borderline resectable pancreatic cancer
  • 2 Adenocarcinoma or Adenosquamuscarcinoma
  • 3 Eastern Cooperative Oncology Group (ECOG) Performance status (PS) 0 or 1
  • 4 No treatment history of chemotherapy and chemoradiotherapy
  • 5 No treatment history of chemotherapy and chemoradiotherapy for pancreatic cancer
  • 6 No diarrhea
  • 7 Orally ingestible
  • 8 Appropriate biliary drainage in case of Obstructive jaundice
  • 9 It has neither homozygote (UGT1A1 6/6,UGT1A1 28/28) nor double heterozygote (UGT1A1 6/28).
  • 10 Adequate organ function
  • 1 White blood cell less than 10.000/mm3
  • 2 Neutrophil more than 1.500/mm3
  • 3 Hemoglobin more than 9.0 g/dL
  • 4 Platelet more than 10000/mm3
  • 5 albumin more than 3.0g/dL
  • 6 Total bilirubin less than 1.5mg/dL
  • 7 AST less than 100U/L
  • 8 ALT less than 100U/L
  • 9 Serum creatinine less than 1.2mg/dL(Male), Serum creatinine less than 1.0mg/dL(Femal)
  • 11 Written informed consent
  • 12 Agree with operation

排除标准

  • 1 Multiple primary cancers with disease-free period less than 5 years
  • 2 Active infection
  • 3 Fever more than 38
  • 5 Uncontrolled mental disease
  • 6 Continuous administration of immunosuppressive drugs including steroids
  • 7 Interstitial pneumonia
  • 8 Serious complications
  • 9 Unstable angina
  • 10 Continuous administration of flucytosine, phenytoin, warfarin potassium
  • 11 Allergy of contrast agent

结局指标

主要结局

-

R0 Resection rate

次要结局

未报告次要终点

研究者

发起方
未提供

相似试验